These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22851205)

  • 41. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
    Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
    Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
    Pauer LR; Olivares J; Cunningham C; Williams A; Grove W; Kraker A; Olson S; Nemunaitis J
    Cancer Invest; 2004; 22(6):886-96. PubMed ID: 15641487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
    Stinchcombe TE; Socinski MA; Walko CM; O'Neil BH; Collichio FA; Ivanova A; Mu H; Hawkins MJ; Goldberg RM; Lindley C; Dees EC
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):759-66. PubMed ID: 17285317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
    Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
    J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
    Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
    Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
    O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
    Schilder RJ; Gallo JM; Millenson MM; Bookman MA; Weiner LM; Rogatko A; Rogers B; Padavic-Shallers K; Boente M; Rosenblum N; Adams AL; Ciccotto S; Ozols RF
    J Clin Oncol; 2001 Feb; 19(4):1183-94. PubMed ID: 11181685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
    Movva S; Verschraegen CF; Rabinowitz I; Mangalik A; Parks V; Lee FC
    Melanoma Res; 2011 Feb; 21(1):76-9. PubMed ID: 21169871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
    Tran HT; Blumenschein GR; Lu C; Meyers CA; Papadimitrakopoulou V; Fossella FV; Zinner R; Madden T; Smythe LG; Puduvalli VK; Munden R; Truong M; Herbst RS
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):308-14. PubMed ID: 15184994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
    Dy GK; Bruzek LM; Croghan GA; Mandrekar S; Erlichman C; Peethambaram P; Pitot HC; Hanson LJ; Reid JM; Furth A; Cheng S; Martell RE; Kaufmann SH; Adjei AA
    Clin Cancer Res; 2005 Mar; 11(5):1877-83. PubMed ID: 15756013
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.
    Jones SF; Bendell JC; Infante JR; Spigel DR; Thompson DS; Yardley DA; Greco FA; Murphy PB; Burris HA
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):225-30. PubMed ID: 21475129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
    Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
    Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
    Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
    Strickler JH; Starodub AN; Jia J; Meadows KL; Nixon AB; Dellinger A; Morse MA; Uronis HE; Marcom PK; Zafar SY; Haley ST; Hurwitz HI
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):251-8. PubMed ID: 22744359
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
    Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S
    Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
    Ready NE; Lipton A; Zhu Y; Statkevich P; Frank E; Curtis D; Bukowski RM
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):576-83. PubMed ID: 17255280
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
    Stathis A; Hotte SJ; Chen EX; Hirte HW; Oza AM; Moretto P; Webster S; Laughlin A; Stayner LA; McGill S; Wang L; Zhang WJ; Espinoza-Delgado I; Holleran JL; Egorin MJ; Siu LL
    Clin Cancer Res; 2011 Mar; 17(6):1582-90. PubMed ID: 21278245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
    Burris HA; Dowlati A; Moss RA; Infante JR; Jones SF; Spigel DR; Levinson KT; Lindquist D; Gainer SD; Dar MM; Suttle AB; Ball HA; Tan AR
    Mol Cancer Ther; 2012 Aug; 11(8):1820-8. PubMed ID: 22679111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.